CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 1188104-1188412 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T27456","span":{"begin":0,"end":308},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The first Abeta immunotherapy trial in Alzheimer's disease (AD), using active immunisation with Abeta42 peptide (AN1792, Elan Pharmaceuticals), was effective in removing plaques but encountered side-effects associated with focal cerebral white matter abnormalities, inflammation and neurological dysfunction."}

{"project":"Epistemic_Statements","denotations":[{"id":"T2585","span":{"begin":0,"end":308},"obj":"Epistemic_statement"}],"text":"The first Abeta immunotherapy trial in Alzheimer's disease (AD), using active immunisation with Abeta42 peptide (AN1792, Elan Pharmaceuticals), was effective in removing plaques but encountered side-effects associated with focal cerebral white matter abnormalities, inflammation and neurological dysfunction."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T23","span":{"begin":0,"end":308},"obj":"Sentence"}],"text":"The first Abeta immunotherapy trial in Alzheimer's disease (AD), using active immunisation with Abeta42 peptide (AN1792, Elan Pharmaceuticals), was effective in removing plaques but encountered side-effects associated with focal cerebral white matter abnormalities, inflammation and neurological dysfunction."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T525","span":{"begin":39,"end":58},"obj":"Phenotype"},{"id":"T526","span":{"begin":60,"end":62},"obj":"Phenotype"},{"id":"T527","span":{"begin":229,"end":264},"obj":"Phenotype"}],"attributes":[{"id":"A525","pred":"hp_id","subj":"T525","obj":"http://purl.obolibrary.org/obo/HP_0002511"},{"id":"A526","pred":"hp_id","subj":"T526","obj":"http://purl.obolibrary.org/obo/HP_0002511"},{"id":"A527","pred":"hp_id","subj":"T527","obj":"http://purl.obolibrary.org/obo/HP_0002500"}],"text":"The first Abeta immunotherapy trial in Alzheimer's disease (AD), using active immunisation with Abeta42 peptide (AN1792, Elan Pharmaceuticals), was effective in removing plaques but encountered side-effects associated with focal cerebral white matter abnormalities, inflammation and neurological dysfunction."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T4883","span":{"begin":238,"end":250},"obj":"Body_part"}],"attributes":[{"id":"A4883","pred":"uberon_id","subj":"T4883","obj":"http://purl.obolibrary.org/obo/UBERON_0002316"}],"text":"The first Abeta immunotherapy trial in Alzheimer's disease (AD), using active immunisation with Abeta42 peptide (AN1792, Elan Pharmaceuticals), was effective in removing plaques but encountered side-effects associated with focal cerebral white matter abnormalities, inflammation and neurological dysfunction."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1310","span":{"begin":39,"end":58},"obj":"Disease"},{"id":"T1311","span":{"begin":60,"end":62},"obj":"Disease"},{"id":"T1312","span":{"begin":266,"end":278},"obj":"Disease"},{"id":"T66335","span":{"begin":39,"end":58},"obj":"Disease"},{"id":"T79767","span":{"begin":60,"end":62},"obj":"Disease"},{"id":"T37166","span":{"begin":266,"end":278},"obj":"Disease"}],"attributes":[{"id":"A1310","pred":"mondo_id","subj":"T1310","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A1311","pred":"mondo_id","subj":"T1311","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A1312","pred":"mondo_id","subj":"T1312","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A67405","pred":"mondo_id","subj":"T66335","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A32561","pred":"mondo_id","subj":"T79767","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A10859","pred":"mondo_id","subj":"T37166","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"}],"text":"The first Abeta immunotherapy trial in Alzheimer's disease (AD), using active immunisation with Abeta42 peptide (AN1792, Elan Pharmaceuticals), was effective in removing plaques but encountered side-effects associated with focal cerebral white matter abnormalities, inflammation and neurological dysfunction."}